p53: functions, mutations and sarcomas
Open Access
- 1 January 1997
- journal article
- other
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 68 (sup273) , 68-73
- https://doi.org/10.1080/17453674.1997.11744705
Abstract
The p53 gene is the most commonly altered gene in a multitude of human cancers. The alterations can be acquired somatically or transmitted through the germ-line. Bone and soft tissue sarcomas are frequently found to have acquired abnormalities in the p53 and mdm-2 genes. In soft tissue sarcoma, the amplification of the mdm-2 gene and the binding of its oncogene product to wild-type p53 protein functionally inactivates normal p53-regulated growth. Inherited mutations of the p53 gene are associated with the rare Li-Fraumeni familial cancer syndrome. Various tumor types arise in these families, with sarcomas of the bone and soft tissues and carcinoma of the breast being the most frequently observed. Transgenic mice with highly expressed mutated p53 have a higher incidence of tumors, including predominantly osteosarcomas and soft tissue sarcomas. In close similarity with the Li-Fraumeni syndrome, homozygously p53-null mice (transgenic mice carrying two non-functional p53 allele) are developmentally normal however they are susceptible to spontaneous tumor formation. This article reviews briefly the structure, function, and dysfunction of the p53 tumor-suppressor gene with particular focus on its role in the development of bone and soft tissue sarcoma.Keywords
This publication has 51 references indexed in Scilit:
- A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53–deficient miceNature Genetics, 1995
- The dominating effect of mutant p53Nature Genetics, 1995
- Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic MutationsScience, 1994
- Inhibition of DNA replication factor RPA by p53Nature, 1993
- Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53Nature, 1993
- p53, guardian of the genomeNature, 1992
- The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivationCell, 1992
- p53 germline mutations in Li-Fraumeni syndromeThe Lancet, 1991
- The p53 tumour suppressor geneNature, 1991
- Mutation and Cancer: Statistical Study of RetinoblastomaProceedings of the National Academy of Sciences, 1971